Jul 11, 2021 04:31 PM (GMT+8)
According to the announcement of Boteng, the net profit in the first half of 2021 is expected to be 210 million yuan – 223 million yuan, with a year-on-year growth of 60% - 70%. Under the background of steady growth of global pharmaceutical R & D pipeline and increasing trend of pharmaceutical R & D outsourcing, the company has continuously consolidated the achievements of cdmo strategic transformation, continuously expanded and enriched product pipeline, continuously improved technical capability and product delivery capability, and continuously improved the company's ability to obtain orders. In the first half of 2021, the company expects to achieve a 30% - 40% increase in operating revenue compared with the same period last year.
This text is a result of machine translation.